Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (68)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Price, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Price, P. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology, Vol 38, 618-626, Copyright © 1999 by British Society for Rheumatology

ORIGINAL PAPERS

Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity

JS Johansen, M Stoltenberg, M Hansen, A Florescu, K Horslev-Petersen, I Lorenzen and PA Price
Department of Rheumatology, Hvidovre Hospital, Denmark.

OBJECTIVE: YKL-40, also called human cartilage glycoprotein-39, is secreted by chondrocytes, synovial cells, macrophages and neutrophils. Studies have shown that YKL-40 is an autoantigen in rheumatoid arthritis (RA). We evaluated whether serum YKL-40 was related to disease activity in patients with RA. METHODS: Serum YKL-40 was determined by radioimmunoassay in 156 patients with RA during a 1 yr longitudinal study. RESULTS: Serum YKL-40 was increased in 54% of the patients with clinically active disease. Patients with clinically active disease initially who became inactive after 12 months had a significant decrease in serum YKL-40 (-30%, P < 0.002) and patients who changed from inactive to active disease had an increase in serum YKL- 40. Patients who remained active had unchanged serum YKL-40 during the study. Serum YKL-40 decreased rapidly (-24% after 7 days, P < 0.01) during prednisolone therapy, and more slowly in patients treated with methotrexate only (-15% after 60 days, P < 0.01). Patients with early RA (disease duration < 3 yr, n = 50) and a persistently elevated serum YKL-40 were at risk of radiological disease progression as determined by Larsen score. CONCLUSION: Serum YKL-40 varies according to disease activity in RA, but provides in some respect information different from conventional markers. Our previous studies are consistent with a local release of YKL-40 in the arthritic joint followed by a secondary increase in serum YKL-40. YKL-40 may prove to be a new tool for the study of disease activity and pathophysiology of RA.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Histochem. Cytochem.Home page
J. S. Johansen, P. E. Hoyer, L. A. Larsen, P. A. Price, and K. Mollgard
YKL-40 Protein Expression in the Early Developing Human Musculoskeletal System
J. Histochem. Cytochem., December 1, 2007; 55(12): 1213 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
L. Deutsch
Evaluation of the Effect of Neptune Krill Oil on Chronic Inflammation and Arthritic Symptoms
J. Am. Coll. Nutr., February 1, 2007; 26(1): 39 - 48.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. F. Bigg, R. Wait, A. D. Rowan, and T. E. Cawston
The Mammalian Chitinase-like Lectin, YKL-40, Binds Specifically to Type I Collagen and Modulates the Rate of Type I Collagen Fibril Formation
J. Biol. Chem., July 28, 2006; 281(30): 21082 - 21095.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price
Serum YKL-40, A New Prognostic Biomarker in Cancer Patients?
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. J. Bergmann, J. S. Johansen, T. W. Klausen, A. K. Mylin, J. S. Kristensen, E. Kjeldsen, and H. E. Johnsen
High Serum Concentration of YKL-40 Is Associated with Short Survival in Patients with Acute Myeloid Leukemia
Clin. Cancer Res., December 15, 2005; 11(24): 8644 - 8652.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. G. A. Steenbakkers, D. Baeten, E. Rovers, E. M. Veys, A. W. M. Rijnders, J. Meijerink, F. De Keyser, and A. M. H. Boots
Localization of MHC Class II/Human Cartilage Glycoprotein-39 Complexes in Synovia of Rheumatoid Arthritis Patients Using Complex-Specific Monoclonal Antibodies
J. Immunol., June 1, 2003; 170(11): 5719 - 5727.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J.-M. Rakic, V. Lambert, M. Deprez, J.-M. Foidart, A. Noel, and C. Munaut
Estrogens Reduce the Expression of YKL-40 in the Retina: Implications for Eye and Joint Diseases
Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1740 - 1746.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Sjogren, J. M. Meis-Kindblom, C. Orndal, P. Bergh, K. Ptaszynski, P. Aman, L.-G. Kindblom, and G. Stenman
Studies on the Molecular Pathogenesis of Extraskeletal Myxoid Chondrosarcoma--Cytogenetic, Molecular Genetic, and cDNA Microarray Analyses
Am. J. Pathol., March 1, 2003; 162(3): 781 - 792.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. C. Tsark, W. Wang, Y.-C. Teng, D. Arkfeld, G. R. Dodge, and S. Kovats
Differential MHC Class II-Mediated Presentation of Rheumatoid Arthritis Autoantigens by Human Dendritic Cells and Macrophages
J. Immunol., December 1, 2002; 169(11): 6625 - 6633.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Tanwar, M. R. Gilbert, and E. C. Holland
Gene Expression Microarray Analysis Reveals YKL-40 to Be a Potential Serum Marker for Malignant Character in Human Glioma
Cancer Res., August 1, 2002; 62(15): 4364 - 4368.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
C. Ostergaard, J. S. Johansen, T. Benfield, P. A. Price, and J. D. Lundgren
YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis
Clin. Vaccine Immunol., May 1, 2002; 9(3): 598 - 604.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. C. Register, C. S. Carlson, and M. R. Adams
Serum YKL-40 Is Associated with Osteoarthritis and Atherosclerosis in Nonhuman Primates
Clin. Chem., December 1, 2001; 47(12): 2159 - 2161.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Gineyts, P. Garnero, and P. D. Delmas
Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation
Rheumatology, March 1, 2001; 40(3): 315 - 323.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. S. Patil, F. C. Hall, S. Drover, D. R. Spurrell, E. Bos, A. P. Cope, G. Sonderstrup, and E. D. Mellins
Autoantigenic HCgp39 Epitopes Are Presented by the HLA-DM-Dependent Presentation Pathway in Human B Cells
J. Immunol., January 1, 2001; 166(1): 33 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T. Conrozier, M-C Carlier, P Mathieu, F Colson, A L Debard, S Richard, H Favret, J Bienvenu, and E Vignon
Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study
Ann Rheum Dis, October 1, 2000; 59(10): 828 - 831.
[Abstract] [Full Text]

Home page
 Ann Rheum DisHome page
K Vos, P Steenbakkers, A M M Miltenburg, E Bos, M W van den Heuvel, R A van Hogezand, R R P de Vries, F C Breedveld, and A M H Boots
Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions
Ann Rheum Dis, July 1, 2000; 59(7): 544 - 548.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.